Legal Suvidha is a registered trademark. Unauthorized use of our brand name or logo is strictly prohibited. All rights to this trademark are protected under Indian intellectual property laws.
Legal Suvidha
Back to Updates
Licenses And Certifications 14 October 2026

FDA Reviews Zydus Keytruda Biosimilar Application

The U.S. Food and Drug Administration has accepted for review a biologics license application submitted by Zydus and its German partner for a biosimilar version of Merck’s Keytruda, moving the Indian biotech closer to the U.S. market. Meanwhile, the SJM party has urged India to block Starlink’s satellite broadband licence request, citing national‑security concerns.

[U.S. FDA](https://timesofindia.indiatimes.com/india/usfda-accepts-biosimilar-application-of-zydus-and-german-firm-for-keytruda/articleshow/134922599.cms) accepts Zydus‑German Keytruda biosimilar BLA
- The FDA has taken the biologics license application (BLA) for a proposed Keytruda biosimilar from Zydus and a German firm for review, bringing the Indian company nearer to launching the drug in the U.S.
- The application was filed in Q3 2026 following earlier moves to secure U.S. rights for similar cancer therapies.

[Starlink](https://money.rediff.com/news/market/sjm-urges-india-to-block-starlink-over-national-security/56132720261013) faces political push in India
- The SJM party urged the government to deny a licence to Elon Musk’s Starlink satellite broadband service, warning it could pose national‑security risks.
- Starlink has applied for permission to operate commercial satellite internet services in India, sparking debate over security versus connectivity benefits.

Need help understanding this update?

Connect with our domain experts instantly via WhatsApp for customized legal guidance.

Chat on WhatsApp

* May contain AI generated content. Please verify the required details.